

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		10595485	
	Filing Date		2006-04-21	
	First Named Inventor	Ezio GHIGO		
	Art Unit	N/A		
	Examiner Name	Not Yet Assigned		
Attorney Docket Number		0290494.00122US1		

U.S. PATENTS						
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1	4554101		1985-11-19	Hopp	

If you wish to add additional U.S. Patent citation information please click the Add button.

U.S. PATENT APPLICATION PUBLICATIONS						
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Published Application citation information please click the Add button.

FOREIGN PATENT DOCUMENTS								
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ² j	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	T ⁵
1	1	03/051389	WO		2003-06-26	Theratechnologies, Inc.		<input type="checkbox"/>
2	2	01/87335	WO		2001-11-22	Eli Lilly and Company		<input type="checkbox"/>
3	3	2470235	CA		2003-06-26	Theratechnologies, Inc.		<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number		10595485
Filing Date		2006-04-21
First Named Inventor	Ezio GHIGO	
Art Unit	N/A	
Examiner Name	Not Yet Assigned	
Attorney Docket Number	0290494.00122US1	

4	4	2471879	CA		2003-11-27	Daiichi Santory Pharma Co., Ltd.	<input type="checkbox"/>
---	---	---------	----	--	------------	----------------------------------	--------------------------

If you wish to add additional Foreign Patent Document citation information please click the Add button

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁵
	1	Adelhorst et al., J. Biol. Chem. 269: 6275-6278, 1994.	<input type="checkbox"/>
	2	BROGLIO et al., "Non Acylated Ghrelin Counteracts the Metabolic but not the Neuroendocrine REsponse to Acylated Ghrelin in Humans", Jorunal of Clinical Endocrinology Metabolism, 89(6):3062-3065 (2004)	<input type="checkbox"/>
	3	CASSONI et al., "Identification, Characterization and Biological Activity of Specific Receptors for Natural (Ghrelin) and Synthetic Growth Hormone Secretagogues and Analogs in Human Breast Carcinomas and Cell Lines", Journal of Clinical Endocrinology and Metabolism, 83(4):1738-1745 (2001)	<input type="checkbox"/>
	4	Granata, Riccarda et al. "Acylated and unacylated ghrelin promote proliferation and inhibit apoptosis of pancreatic beta cells and human islets: involvement of 3', 5'- cyclic adenosine monophosphate/protein kinase A, extracellular signal-regulated kinase 1/2, and phosphatidylinositol 3-kinase/Akt signaling." Endocrinology, February 2007, 148(2), pages 512-529	<input type="checkbox"/>
	5	Granata, Riccarda et al. "Acylated and unacylated ghrelin promote proliferation and inhibit serum starvation- and cytokine-induced apoptosis of pancreatic beta cells through cAMP/PKA, ERK1/2 and P13K/Akt.", abstract and poster presented at "Endocrine Society Meeting," Boston, from June 24, 2006-June 27, 2006.	<input type="checkbox"/>
	6	International Search Report, PCT/CA2002/001964	<input type="checkbox"/>
	7	International Search Report, PCT/CA2004/001858	<input type="checkbox"/>
	8	Marzullo et al., J. Clin. Endocr. Metab. 89: 936-939, 2004.	<input type="checkbox"/>

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number	10595485
Filing Date	2006-04-21
First Named Inventor	Ezio GHIGO
Art Unit	N/A
Examiner Name	Not Yet Assigned
Attorney Docket Number	0290494.00122US1

9	Mickle et al., Medical Clin. North Am., 2000, Vol. 84(3), p. 597-607.	<input type="checkbox"/>
10	POYKKO, et al., "Low Plasma Ghrelin is Associated with Insulin REsistance, Hypertension and the Prevalence of Type 2 Diabetes", Diabetes, 52:2546-2553 (2003)	<input type="checkbox"/>
11	Prodan, Flavia et al. "Unacylated ghrelin (UAG) enhances the early insulin response to meal, improves glucose metabolism and decrease free fatty acids levels in healthy volunteers." Abstract and poster presented at "European Congress of Endocrinology," Budapest, from April 28, 2007--May 2, 2007.	<input type="checkbox"/>
12	TOSHINAI, et al., "Upregulation of Ghrelin Expression in the Stomach upon Fastin, Insulin-Induced Hypoglycemia and Leptin Administration", Biochemical and Biophysical Research Communications, 281(5):1220-1225 (2001)	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

Examiner Signature	/Gyan Chandra/	Date Considered	08/18/2009
--------------------	----------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.